Comparison of the Effect of Device Closure in Alleviating Migraine With Patent Foramen Oval: COMPETE Cohort Study
Migraine attacks are episodic disorder that affects approximately 12% of the population, and studies have shown that 41-48% of migraineurs have a combination of patent foramen ovale (PFO). Clinical Observational studies have been linking PFO occlusion with the effectiveness in improving migraine symptoms and reducing the frequency of attacks. However, several RCTs have shown negative primary results, making it unclear whether PFO occlusion is effective in treating migraine. Our study is a multi-center cohort study aiming to find the correlation between PFO closure and migraine attacks.
• Age 18-65 ;
• Diagnosed migraine by ICHD-3
• History of migraine longer than 1 year, and symptoms severely disturbing daily life.
• TCD/TTE/TEE diagnosed patent foramen ovale with right to left shunt
• Willing to participant and agree to follow-ups
• Received at least three different types of migraine preventive drugs, the responder rate of previous therapy did not receive 50%.